Answer
Yes, progressive multifocal leukoencephalopathy (PML) has been reported with Jakavi (ruxolitinib phosphate), and if PML is suspected, further dosing must be suspended until PML has been excluded.
Sources for this answer
- Jakavi 5mg, 10mg, 15mg and 20mg TabletsNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 29Document updated
Sources checked